- Ming-Lung Yu, MD, PhD
- Professor, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Website | E-mail
Special Issue Introduction
Chronic hepatitis C (CHC) infection is one of the major etiologies of hepatocellular carcinoma (HCC). As with the observations in the interferon era, treating patients with directly acting antivirals significantly reduces HCC risk. However, the risk ratio reduction may be more limited in patients who already possess decompensated liver cirrhosis. In terms of HCC recurrence, it has been suggested that HCC may recur more frequently and aggressively after DAA intervention. The difficulty in performing a prospective study comparing to non-treatment cohort may render inconclusive results. The issue of washout period between curative HCC treatment and initiating DAA treatment may also determine the interpreting of the outcomes. With more evidence emerging, the HCV eradication by DAA should not have a negative impact on HCC recurrence.
From another perspective, whether the presence of active HCC would compromise DAA treatment efficacy remains an area of uncertainty. The discrepant results may arise from diverse patient characteristics and treatment regimens. The long-term survival benefit of HCV eradication in patients with active HCC remains to be studied. In this issue, the interaction between DAA and HCC will be reviewed.
Participants1. Raymond T. Chung&Stephanie Marie Rutledge Massachusetts General Hospital, Harvard Medical School, Boston, USA.
2. Suna Yapali Division of Gastroenterology and Hepatology, Acibadem Mehmet Ali Aydinlar University, Turkey.
3. Tathagata Choudhuri Visva-Bharati University, Santiniketan, India.
4. Ming Yang Beijing Tsinghua Changgung Hospital, Beijing, China.
5. Mario Pirisi Università del Piemonte Orientale, Novara, Italy.
6. Stefano Brillanti Alma Mater Studiorum Università di Bologna, Bologna, Italy.
7. Tatsuo Kanda Nihon University School of Medicine, Tokyo, Japan.
8. Mohamed Kohla Menoufia University, Shebin El Kom, Egypt.
9. Sandra Ciesek Institute of Medical Virology, University Hospital Frankfurt, Frankfurt, Germany.
10. Mohamed El Kassas Helwan University, Cairo, Egypt.
11. Wen-Juei Jeng&Wei Teng Chang Gung Memorial Hospital, Linkou branch, Taiwan.
12. Chia-Yen Dai Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
13. Zahari A. Krastev Sveti Ivan Rilski hospital, Sofia, Bulgaria.
14. Jung Hyun Kwon&Sun Hong Yoo The Catholic University of Korea, Seoul, South Korea.
15. Juan Socorro Armendariz-Borunda, Christian Monroy&Laura Sanchez Tecnologico de Monterrey, Monterrey, Mexico.
16. Erica Villa Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
17. David E Bernstein&Tai-Ping Lee Hofstra Northwell School of Medicine, Hempstead, USA.
The list is arranged in no particular order and being updated.
Submission Deadline30 Nov 2019